Dolby Laboratories (DLB) News & Sentiment

DLB is a promising investment option due to its strengths in Dolby Atmos and Dolby Vision, the benefits from recent acquisitions, and its commitment to returning value to shareholders.

Dolby Laboratories announced a 13% increase in revenue compared to the same period last year for the first quarter of 2025, largely due to timing differences, and they have a somewhat better outlook. The company has $521 million in cash and no debt, but its stock has not performed as well as the iShares Expanded Technology-Software ETF. They expect revenue growth of 3.2% for this fiscal year, with some potential in mobile and cinema products, although significant drivers for growth are not expected.

Dolby Laboratories (DLB) has passed our "Recent Price Strength" test, making it a strong option for investors interested in stocks that are gaining momentum.

The study showed significant positive effects on behavior, function, cognition, and movement in patients with mild to moderate DLB.

Dolby Laboratories (DLB) reported quarterly earnings of $1.14 per share, which is higher than the Zacks Consensus Estimate of $1.07 per share. This is an increase compared to earnings of $1.01 per share from the same period last year.

SAN FRANCISCO, Jan. 29, 2025 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) has released its financial results for the first quarter of fiscal 2025. Kevin Yeaman, the President and CEO of Dolby Laboratories, stated, "We have made a strong beginning for FY25."

DLB's financial results for the first quarter are expected to have improved due to the popularity of Dolby Atmos and Dolby Vision, even though device sales have been weak.

Stocks such as DLB, CCL, NFLX, and AOUT are likely to gain from the positive outlook on interest rate reductions.

Dolby Laboratories (DLB) may not have the right mix of the two important factors needed for a potential earnings surprise in its next report. Be ready for the main expectations.